Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | CTSS | P25774 | 8/20 | 0.56 |
| ▸ | CTSL | P07711 | 7/20 | 0.56 |
| ▸ | CTSB | P07858 | 6/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779459 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL6358961 | 0.85 | ATM (0.58) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL398460 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL1547277 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL4033719 | 0.83 | NPC1 (0.65) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL6407665 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL5268187 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL13572927 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL13534727 | 0.83 | NPC1 (0.65) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL14999596 | 0.83 | ATM (0.59) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | CTSK 1509/4885CTSS 2004/4885CTSL 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.